In September, the Food and Drug Administration (FDA) strengthened a warning that linked diabetes drug Invokana to an increased risk of bone fractures. The warning came as the result of various separate clinical studies showing that the medication reduced bone density in patients, and caused severe fractures. The FDA will continue to monitor Invokana and other SLGT2 inhibitors for adverse effects, but has cautioned physicians to consider the risks before prescribing the medication to patients. Read more about the FDA warnings.
For more information about the adverse effects of Invokana, and lawsuits related to the drug, contact the experienced pharmaceutical liability attorneys at the Law Offices of Peter G. Angelos.